Fate Therapeutics FATE 深 滬
等待開盤 10-10 09:30:00 美东时间
1.63
+0.120
+7.95%
華盛通- 最 高1.66
- 今 開1.52
- 成交量 517.37万股
- 最 低 1.43
- 昨 收 1.51
- 總市值 1.87亿
- 52周最高 3.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6611
- 委 比 47.25%
- 總股本 1.15亿
- 歷史最高 121.16
- 量 比 1.42
- 振 幅 15.23%
- 歷史最低 0.6611
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多申城秋韵｜全球最大规模，超12万人次打卡！“二次元”在这里“买买买”
等候入场的观众，主办方提供 10月2日上午7时30分，距离入场时间还有近两小时，手办模型爱好者李立到达上海新国际博览中心的普通票观众通道时，早已有人守候。这时...
10-03 16:45
吸引超2000名展商、12万人次打卡，B站举办全球最大规模手办模型展
（来源：三文娱） 10月2日至10月3日，由B站独家承办的手办模型展 Wonder Festival 2025（以下简称“WF2025”）在上海新国际博览中心...
10-03 11:33
美股牛股 | ANAB大涨超31%！宣布重大业务重组计划；Wolfspeed再涨超29%，宣布脱离破产保护
ANAB大涨超31%！宣布重大业务重组计划；Wolfspeed再涨超29%，宣布脱离破产保护；MFH昨日涨近26%，美国SEC释放监管利好信号>>
10-01 20:34
硬核实力再获认可！广电运通在算法与数据应用领域取得多项突破
核心导读 近日，广电运通各成员企业在前沿技术创新、国内数据应用领域与市场拓展持续取得重大突破，始终坚持用硬核实力诠释行业自信，以实际行动彰显企业使命。像素数据...
09-01 18:04
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies, announced its participation in two upcoming investor conferences: the 2025 Wells Fargo Healthcare Conference on September 3, 2025, in Boston, MA, and the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York, NY. The Company will host one-on-one meetings and a fireside chat during these events. Live and archived web...
08-25 12:00
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $2.5
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $4 to $2.5.
08-13 20:52
Fate Therapeutics Announces Corporate Restructuring Plan
An update from Fate Therapeutics ( ($FATE) ) is now available. On August 7, 202...
08-13 04:44
Fate Therapeutics Q2 EPS $(0.29) Beats $(0.34) Estimate, Sales $1.907M Beat $1.011M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.34) by 14.71 percent. This is a 12.12 percent increase over losses of $(0.33) per share from
08-13 04:17
Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported progress in its FT819 CAR T-cell therapy for autoimmune diseases, including positive interim data in lupus nephritis and extrarenal lupus, and expanded its Phase 1 trial to include additional B cell-mediated autoimmune diseases. The company also amended its collaboration with Ono Pharmaceuticals for a second solid tumor CAR T-cell candidate. Additionally, the FDA allowed the IND application for FT836, an MICA/B-targeted...
08-12 20:01
